RPG Life Sciences Ltd
RPG Life Sciences Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on RPG Life Sciences Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Revenue from Operations: - Q2 FY25: ₹172.2 Crores - Q2 FY24: ₹153.6 Crores - YoY Growth: +12.1% - Sales Growth by Segments (H1 FY25 vs H1 FY24): - Domestic Formulations (66% of sales): 10% growth - API (15% of sales): 14% growth - International Formulations (19% of sales): 16% growth - Volume Information: Not explicitly stated. - Outlook: - Focus on scaling up business through comprehensive 7 pillars including innovation, capacity expansion, and talent acquisition (Page 43). Q2 FY25 EBITDA: Rs.
From RPG Life Sciences Ltd's Q2 FY25 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations:
- Q2 FY25: ₹172.2 Crores
- Q2 FY24: ₹153.6 Crores
- YoY Growth: +12.1%
- Sales Growth by Segments (H1 FY25 vs H1 FY24):
- Domestic Formulations (66% of sales): 10% growth
- API (15% of sales): 14% growth
- International Formulations (19% of sales): 16% growth
- Volume Information: Not explicitly stated.
- Outlook:
- Focus on scaling up business through comprehensive 7 pillars including innovation, capacity expansion, and talent acquisition (Page 43).
- Emphasis on revenue growth via new products, markets & customers, and sustained cost control (Page 42).
2 more points management made on revenue & sales performance
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).
- Modernization and capacity expansion of formulations and API plants highlighted as part of business growth strategy (Page 42).
- State-of-the-art, modern, cost-efficient cGMP compliant plants approved by EU/PICS/TGA with ~2X higher capacity targeted for niche-focused R&D pipeline (Page 43).
- Plant modernization and capacity expansion are ongoing transformation projects (Page 11).
- Infrastructure includes a state-of-art EU/TGA-approved plant with enhanced capacity supporting API business (Page 32).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
RPG Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹177 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt Ltd (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma Ltd (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Themis Medicare Ltd (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were RPG Life Sciences Ltd Q2 FY25 results?
Revenue from Operations: - Q2 FY25: ₹172.2 Crores - Q2 FY24: ₹153.6 Crores - YoY Growth: +12.1% - Sales Growth by Segments (H1 FY25 vs H1 FY24): - Domestic Formulations (66% of sales): 10% growth - API (15% of sales): 14% growth - International Formulations (19% of sales): 16% growth - Volume Information: Not explicitly stated. - Outlook: - Focus on scaling up business through comprehensive 7 pillars including innovation, capacity expansion, and talent acquisition (Page 43). Q2 FY25 EBITDA: Rs.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Capex infusion of ~₹140 crore aimed at expanding global play (Page 12).
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.